Dale M Kolstad, LCSW | |
200 E La Crosse St, Juneau County Human Services, Mauston, WI 53948-2101 | |
(608) 847-2400 | |
(608) 847-9599 |
Full Name | Dale M Kolstad |
---|---|
Gender | Male |
Speciality | Social Worker |
Location | 200 E La Crosse St, Mauston, Wisconsin |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1427016955 | NPI | - | NPPES |
39218500 | Medicaid | WI |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YP2500X | Counselor - Professional | 1016125 (Wisconsin) | Primary |
104100000X | Social Worker | 4042123 (Wisconsin) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dale M Kolstad, LCSW 200 E La Crosse St, Juneau County Human Services, Mauston, WI 53948-2101 Ph: (608) 847-2400 | Dale M Kolstad, LCSW 200 E La Crosse St, Juneau County Human Services, Mauston, WI 53948-2101 Ph: (608) 847-2400 |
News Archive
Biodel Inc. announced today that it has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates. The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed meal time insulin analogs while maintaining an injection site tolerability profile comparable to currently marketed insulins.
Heart failure patients have a 2% increased risk of dying with each admission to NHS hospitals, according to research presented at ESC Congress 2016 today.
Entest BioMedical Inc. (OTCBB: ENTB) announced today that it has signed a Letter of Intent with Quantum Advisors, a San Diego based biotechnology consulting firm, to assist Entest with the development of its Stem Cell Therapeutic Treatment for Chronic Obstructive Pulmonary Disease (COPD).
A team of scientists from the USA has recently predicted the driver mutations that may appear in future variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The prediction is based on currently available genetic surveillance data on amino acid mutations present in SARS-CoV-2 variants. A detailed description of the study is currently available on the medRxiv* preprint server.
› Verified 4 days ago